These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12176522)

  • 1. A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts.
    Youseff N; Small S
    Transplant Proc; 2002 Aug; 34(5):1653-5. PubMed ID: 12176522
    [No Abstract]   [Full Text] [Related]  

  • 2. Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.
    Ponticelli C
    Transplant Proc; 2001; 33(1-2):1031-2. PubMed ID: 11267177
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients.
    Hricik DE
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S11-5. PubMed ID: 11583939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
    Lo A; Egidi MF; Gaber LW; Shokouh-Amiri MH; Nazakatgoo N; Fisher JS; Gaber AO
    Clin Transplant; 2004 Feb; 18(1):53-61. PubMed ID: 15108771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity.
    Diekmann F; Waiser J; Fritsche L; Dragun D; Neumayer HH; Budde K
    Transplant Proc; 2001; 33(7-8):3234-5. PubMed ID: 11750386
    [No Abstract]   [Full Text] [Related]  

  • 6. Steroid withdrawal in renal transplant recipients.
    Oppenheimer F
    Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
    [No Abstract]   [Full Text] [Related]  

  • 7. Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan.
    Akiyama T; Okazaki H; Takahashi K; Hasegawa A; Tanabe K; Uchida K; Takahara S; Toma H
    Transplant Proc; 2005 Mar; 37(2):843-5. PubMed ID: 15848551
    [No Abstract]   [Full Text] [Related]  

  • 8. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J; Wiseman AC
    Transplantation; 2009 Jun; 87(11):1712-9. PubMed ID: 19502965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved outcome of minor-mismatched living renal allografts under tacrolimus immunosuppression.
    Tanabe K; Ishida H; Tokumoto T; Shimmura H; Toda F; Omoto K; Makiyama K; Yagisawa T; Fuchinoue S; Teraoka S; Toma H
    Transplant Proc; 2002 Aug; 34(5):1668-70. PubMed ID: 12176528
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression.
    Toda F; Tanabe K; Tokumoto T; Ishikawa N; Koga S; Ito S; Yagisawa T; Toma H
    Transplant Proc; 2000 Nov; 32(7):1726-9. PubMed ID: 11119909
    [No Abstract]   [Full Text] [Related]  

  • 12. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience.
    Tanabe K; Ishikawa N; Tokumoto T; Takahashi K; Kanematsu A; Kitani R; Fuchinoue S; Oshima T; Yagisawa T; Toma H
    Transplant Proc; 1998 Jun; 30(4):1224-6. PubMed ID: 9636497
    [No Abstract]   [Full Text] [Related]  

  • 14. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.
    MacDonald AS;
    Transplantation; 2001 Jan; 71(2):271-80. PubMed ID: 11213073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients.
    El-Sabrout R; Weiss R; Butt F; Delaney V; Qadir M; Hanson P; Butt K
    Transplant Proc; 2002 Aug; 34(5):1942-3. PubMed ID: 12176636
    [No Abstract]   [Full Text] [Related]  

  • 19. A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation.
    Sperschneider H;
    Transplant Proc; 2001; 33(1-2):1279-81. PubMed ID: 11267291
    [No Abstract]   [Full Text] [Related]  

  • 20. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience.
    El-Sabrout R; Delaney V; Qadir M; Butt F; Hanson P; Butt KM
    Transplant Proc; 2003 May; 35(3 Suppl):89S-94S. PubMed ID: 12742474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.